Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
CA 2325013 A1 · Owner: Isis Pharmaceuticals Inc. · Inventors: Cowsert, Lex M.; Wyatt, Jacqueline R.; Sasmor, Henri M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Iterative, preferably computer based iterative processes for generating synthetic compounds with desired physical chemical and/or bioactive , properties i.e. active compounds, are provided. During iterations of the processes, a target nucleic acid sequence is provided or selected and a , library of candidate nucleobase sequences is generated in silico according to defined criteria. A "virtual" oligonucleotide chemistry is chosen and a library of virtual oligonucleotide compounds having the selected nucleobase sequences is generated. These virtual compounds are reviewed and compounds predicted to have particular properties are selected. The selected compounds are robotically …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 13, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 13, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 13, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.